Our study reveals that the NF-κB pathway is an important effector of FGFR2 fusions in ICC, with FGFR inhibition leading to rapid loss of MEK-ERK signaling and consequent reduction in NF-κB activity. The gene discussed is FGFR2; the disease is intrahepatic cholangiocarcinoma.